Enterprise Value

100.2M

Cash

51.0M

Avg Qtr Burn

-3.741M

Short % of Float

8.84%

Insider Ownership

35.07%

Institutional Own.

9.93%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPro1595 Details
Alzheimer's disease

Phase 2

Data readout

LIVNate Details
NASH-induced significant or severe fibrosis, Liver disease

Phase 2

Update

INB03 + trastuzumab-deruxtecan Details
Cancer, Pancreatic cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer , Gastric cancer

Phase 2

Initiation

XPro1595 (pegipanermin fr) Details
Major depressive disorder, Mental health, Treatment Resistant Depression

Phase 2

Initiation

INKmune™ Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Phase 1/2

Initiation

INKmune™ Details
Cancer, Myelodysplastic syndrome, Acute myeloid leukemia

Phase 1

Data readout

Failed

Discontinued